Carisbamate
Key facts
Active substance |
Carisbamate
|
Therapeutic area |
Neurology
|
Decision number |
P/108/2009
|
PIP number |
Carisbamate
|
Pharmaceutical form(s) |
|
Condition(s) / indication(s) |
|
Route(s) of administration |
|
Contact for public enquiries |
Janssen Cilag International NV (Belgium)
E-mail: bbyl@its.jnj.com |
Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|